EMA Authorised: Sarclisa (Isatuximab) — Sanofi Winthrop Industrie

View source ↗

Summary

The European Medicines Agency has authorised Sarclisa (isatuximab) for the treatment of multiple myeloma, decision date 18 July 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• SARCLISA (isatuximab)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Sanofi Winthrop Industrie. Decision date: 18/07/2025